News | January 30, 2012

VAP Test Improves ID of Carotid Intima-Media Thickness Progression

January 30, 2012 — Expanded cholesterol assessment of moderate risk patients can play an important role in identifying and monitoring the progression of atherosclerosis. That’s according to a clinical study that used the Vertical Auto Profile (VAP) cholesterol test to analyze lipids potentially associated with carotid intima-media thickness (CIMT).

The study; Indicators of the Atherogenic Lipoprotein Phenotype Measured with Density Gradient Ultracentrifugation Predict Changes in Carotid Intima-Media Thickness in Men and Women was published in the January 2012 issue of Vascular Health and Risk Management. The sub-analysis demonstrated that using the VAP test density gradient ultracentrifugation (DGU) method, researchers were able to get a detailed look at how lipoproteins and their subfractions were associated with CIMT progression in men and women at moderate coronary heart disease (CHD) risk.

The study analyzed subjects from the control arm of an earlier double-blind, randomized, clinical trial designed to evaluate the effects of consumption of pomegranate juice compared to a control beverage on CIMT over a period of 18 months. Researchers investigated the relationships between baseline lipoprotein cholesterol, triglyceride (TG) and apolipoprotein B (apoB) levels assessed with the VAP Test and progression of posterior wall common CIMT in men and women at moderate risk of CHD.

Researchers reported that higher levels of TG-rich lipoprotein cholesterol, lower levels of HDL and HDL subfractions, and a greater proportion of LDL carried by more dense LDL particles were associated with CIMT progression in men and women at moderate risk for CHD. The atherogenic lipoprotein phenotype identified by the VAP Test is more strongly associated with CIMT progression than LDL, Non-HDL and apoB concentrations.

The atherogenic phenotype may have an important role in the initiation and progression of early atherosclerosis, and Maki said the data should provide clinicians with useful information to better predict CHD risk and more clearly understand the importance of measurement of lipoprotein subspecies.

The VAP Test is a direct and comprehensive measurement of cholesterol markers associated with heart disease, providing accurate information that can effectively identify and target risk in clinical care. The VAP Test identifies a significantly greater number of people at risk for heart disease than the standard cholesterol test.

For more information:

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init